Proactive versus reactive M&amp;A activities in the biotechnology industry

Haeussler, Carolin

doi:10.1016/j.hitech.2006.11.001

Cited by 10 publications

(5 citation statements)

References 37 publications

(34 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…These results confirm our second hypothesis too, in the sense that the disappearance of biotechnology firms is not due, solely, to bankruptcy; but mainly to M&A (Haeussler, 2007) and changes in name (Carroll and Hannan, 1995). Thus, our sample of 552 DBFs reveals that almost two thirds of disappearances are due to M&A, and that a quarter of the firms have been involved in M&A.…”

Section: Sample Main Characteristicssupporting

confidence: 84%

“…For their part, Danzon et al (2006) show that small firms, having financial problems and few commercial products, have a higher chance of being involved in M&A. Nevertheless, Haeussler (2007) did not find a significant statistical relationship to affirm that financial trouble was a decisive factor for firms engaging in M&A. This type of disappearance has more to do with the strategic visions of the executives than with a reactive action derived from a lack of financial resources.…”

Section: Disappearance Of Dbfsmentioning

confidence: 91%

“…This type of disappearance has more to do with the strategic visions of the executives than with a reactive action derived from a lack of financial resources. Haeussler (2007) reveals that Biotechnology firms having inter-firm collaborations are more likely to engage in M&A.…”

Section: Disappearance Of Dbfsmentioning

confidence: 99%

See 2 more Smart Citations

The disappearance of dedicated biotechnology firms in Canada

Moustakbal¹

2014

IJBT

View full text Add to dashboard Cite

Abstract:The present paper has the objective of understanding the disappearance of biotechnology firms. To accomplish this objective, a sample was built from 552 firms operating in Canada between 1996 and 2010. The results reveal that disappearance is not only due to filing for bankruptcy, but also due to change in firms' names, as well as mergers and acquisitions (M&A). Statistical tests further show that the survival of dedicated biotechnology firms (DBFs) depends mainly on two factors: having a qualified management team, and receiving the support of the venture capital firms. In addition, the results demonstrate that firms which mainly operate in the human health sector and have already received support from VC opt for M&A to exit the industry. This study has some practical lessons for different stakeholders concerning the survival and the exit of new enterprise biotechnology firms.

show abstract

Section: Sample Main Characteristicssupporting

confidence: 84%

Section: Disappearance Of Dbfsmentioning

confidence: 91%

See 1 more Smart Citation

The disappearance of dedicated biotechnology firms in Canada

Moustakbal¹

2014

IJBT

View full text Add to dashboard Cite

show abstract

“…In the beginning of a new technology, funding in a specific field by a competitor can lead others to fund similarly in that field [50]. The firms with greater inter-firm collaboration are more frequently involved in mergers and acquisitions which are not related to monetary problems [51]. Inter-firm collaborations are thought to provide more assets and legitimacy which can protect firms from unfavorable situations [52].…”

Section: Strategic Alliancesmentioning

confidence: 99%

Challenge-based approaches for policy-making in vaccine development and production

Marandi

Tabatabaeian

Jafari

et al. 2018

vacres

View full text Add to dashboard Cite

Presently, vaccines development and production has gained more importance due to their influence on topics such as the society's health system and economy, as well as the bio-security issues and the defense affairs. Moreover, the potential innovation capabilities in vaccine production are assumed as engines of biotechnology development which is among the emerging technologies that can support the technological development of a country. This review is based on analyses of scientific articles, literature, textbooks and reports by the international organization, as well as online databases with the subject of innovation in vaccine production, in order to identify current challenges in vaccine development and production. Not long ago, the most important challenges in this field were assumed as technical or budgetary issues. However nowadays, due to a global paradigm-shift in vaccine production which has changed from innovation aimed solely at the registration of new products toward promoting public health, other challenges in competition and commercialization have stepped in. The identified new challenges and bottlenecks could be used to form practical approaches in policy-making toward vaccine development and production. Furthermore, overcoming these challenges requires identifying the bottlenecks and proper orientation with the current world circumstances to draft a functional policy that could fulfill the national health system objectives. Here, following explaining these global challenges and approaches, the situation of vaccine industry in Iran will be briefly discussed.

show abstract

“…The same mechanism holds for the firm level. Several studies show that biotechnology firms involved in an intense collaboration network bring products to the market faster (Rothaermel and Deeds (2004)), attract more capital (Stuart et al (1999)), and are more likely to restructure in times of change (Häussler (2007)). …”

Section: Literature Review and Theoretical Considerationsmentioning

confidence: 99%

Cluster Performance Reconsidered: Structure, Linkages and Paths in the German Biotechnology Industry, 1996–2003

Häussler¹,

Zademach²

2007

Schmalenbach Bus Rev

View full text Add to dashboard Cite

We examine the evolution of biotechnology clusters in germany between 1996 and 2003, paying particular attention to their composition in terms of venture capital, basic science institutions, and biotechnology firms. drawing upon the significance of co-location of "money and ideas", the literature stressing the importance of a cluster's openness and external linkages, and the path dependency debate, we analyze how certain cluster characteristics correspond with each cluster's overall performance. after defining different cluster types, we explore and compare the clusters' internal and external interconnectivity, and investigate the extent to which the clusters' structural composition has changed over time. our results indicate that the structure, i.e., the type of cluster, and the cluster's openness towards receiving external knowledge provide merely unsystematic indications of a cluster's overall success. the cluster's ability to modify its composition to a more balanced ratio of science and capital over time, in contrast, turns out to be a key explanatory factor. Jel-classification: l22, o18, o32.

show abstract

Proactive versus reactive M&A activities in the biotechnology industry

Cited by 10 publications

References 37 publications

The disappearance of dedicated biotechnology firms in Canada

The disappearance of dedicated biotechnology firms in Canada

Challenge-based approaches for policy-making in vaccine development and production

Cluster Performance Reconsidered: Structure, Linkages and Paths in the German Biotechnology Industry, 1996–2003

Contact Info

Product

Resources

About